<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25182709</article-id><article-id pub-id-type="pmc">4190385</article-id><article-id pub-id-type="publisher-id">488</article-id><article-id pub-id-type="doi">10.1186/s13054-014-0488-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Renal effects of treatment with a TLR4 inhibitor in conscious septic sheep</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fenhammar</surname><given-names>Johan</given-names></name><address><email>johan.fenhammar@karolinska.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Rundgren</surname><given-names>Mats</given-names></name><address><email>Mats.Rundgren@ki.se</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hultenby</surname><given-names>Kjell</given-names></name><address><email>Kjell.Hultenby@ki.se</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Forestier</surname><given-names>Jakob</given-names></name><address><email>jakob.forestier@karolinska.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Taavo</surname><given-names>Micael</given-names></name><address><email>micael.taavo@surgsci.uu.se</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Kenne</surname><given-names>Ellinor</given-names></name><address><email>Ellinor.Kenne@ki.se</email></address><xref ref-type="aff" rid="Aff5"/><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Weitzberg</surname><given-names>Eddie</given-names></name><address><email>Eddie.Weitzberg@ki.se</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Stefan</given-names></name><address><email>Stefan.Eriksson@ki.se</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Ozenci</surname><given-names>Volkan</given-names></name><address><email>Volkan.Ozenci@ki.se</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Wernerson</surname><given-names>Annika</given-names></name><address><email>Annika.Wernerson@ki.se</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Frithiof</surname><given-names>Robert</given-names></name><address><email>robert.frithiof@surgsci.uu.se</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Department of Anesthesia and Intensive Care, Karolinska University Hospital, Department of Clinical Science Intervention and Technology, Karolinska Institutet, H&#x000e4;lsov&#x000e4;gen 13, 14157 Huddinge, Sweden </aff><aff id="Aff2"><label/>Department of Physiology and Pharmacology, Karolinska Institutet, von Eulers v&#x000e4;g 8, 17177 Stockholm, Sweden </aff><aff id="Aff3"><label/>Department of Laboratory Medicine, Division of KFC, Karolinska Institutet, H&#x000e4;lsov&#x000e4;gen 13, 14157 Huddinge, Sweden </aff><aff id="Aff4"><label/>Department of Surgical Sciences, Section of Anaesthesiology &#x00026; Intensive Care, Uppsala University, Sjukhusv&#x000e4;gen 1, 75185 Uppsala, Sweden </aff><aff id="Aff5"><label/>Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska v&#x000e4;gen 1, 17176 Stockholm, Sweden </aff><aff id="Aff6"><label/>Center of Molecular Medicine, Karolinska University Hospital, Karolinska v&#x000e4;gen 1, 17176 Stockholm, Sweden </aff><aff id="Aff7"><label/>Division of Clinical Microbiology, Karolinska Institutet, Karolinska University Hospital, H&#x000e4;lsov&#x000e4;gen 13, 14157 Huddinge, Sweden </aff><aff id="Aff8"><label/>Department of Clinical Science Intervention and Technology, Division of Renal Medicine, Karolinska Institutet, H&#x000e4;lsov&#x000e4;gen 13, 14157 Huddinge, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>18</volume><issue>5</issue><elocation-id>488</elocation-id><history><date date-type="received"><day>18</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>4</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Fenhammar et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Acute kidney injury (AKI) is a common and feared complication of sepsis. The pathogenesis of sepsis-induced AKI is largely unknown, and therapeutic interventions are mainly supportive. In the present study, we tested the hypothesis that pharmacological inhibition of Toll-like receptor 4 (TLR4) would improve renal function and reduce renal damage in experimental sepsis, even after AKI had already developed.</p></sec><sec><title>Methods</title><p>Sheep were surgically instrumented and subjected to a 36-hour intravenous infusion of live <italic>Escherichia coli</italic>. After 12&#x000a0;hours, they were randomized to treatment with a selective TLR4 inhibitor (TAK-242) or vehicle.</p></sec><sec><title>Results</title><p>The <italic>E. coli</italic> caused normotensive sepsis characterized by fever, increased cardiac index, hyperlactemia, oliguria, and decreased creatinine clearance. TAK-242 significantly improved creatinine clearance and urine output. The increase in N-acetyl-beta-D-glucosaminidas, a marker of tubular damage, was attenuated. Furthermore, TAK-242 reduced the renal neutrophil accumulation and glomerular endothelial swelling caused by sepsis. These effects were independent of changes in renal artery blood flow and renal microvascular perfusion in both cortex and medulla. TAK-242 had no effect per se on the measured parameters.</p></sec><sec><title>Conclusions</title><p>These results show that treatment with a TLR4 inhibitor is able to reverse a manifest impairment in renal function caused by sepsis. In addition, the results provide evidence that the mechanism underlying the effect of TAK-242 on renal function does not involve improved macro-circulation or micro-circulation, enhanced renal oxygen delivery, or attenuation of tubular necrosis. TLR4-mediated inflammation resulting in glomerular endothelial swelling may be an important part of the pathogenesis underlying Gram-negative septic acute kidney injury.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13054-014-0488-y) contains supplementary material, which is available to authorized users.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Acute kidney injury (AKI) is an important contributor to morbidity and mortality among hospitalized patients. Sepsis is the leading cause of AKI in the critically ill patient, and currently no effective treatment exists [<xref ref-type="bibr" rid="CR1">1</xref>]. Septic AKI is generally believed to be due to regional hypoperfusion causing renal ischemia [<xref ref-type="bibr" rid="CR2">2</xref>]. However, recent experimental reports indicate that AKI may develop even though renal blood flow and blood pressure remain within physiological limits [<xref ref-type="bibr" rid="CR3">3</xref>-<xref ref-type="bibr" rid="CR5">5</xref>]. Thus, it is possible that the pathogenesis of septic AKI is complicated by factors other than ischemia. In line with this, we wanted to investigate whether an important receptor for initiating inflammation, the Toll-like receptor 4 (TLR4), participates in the pathophysiology of <italic>Escherichia coli</italic>-induced AKI. TLRs have been identified as pivotal mediators in host defense as they are crucial in pathogen recognition and activation of the immune response [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>]. The main ligand for TLR4 is lipopolysaccharide (LPS), a component of the cell membrane of Gram-negative bacteria [<xref ref-type="bibr" rid="CR8">8</xref>-<xref ref-type="bibr" rid="CR10">10</xref>]. When LPS binds to TLR4, an inflammatory response is initiated via production and release of cytokines as well as stimulation of inflammatory cells [<xref ref-type="bibr" rid="CR11">11</xref>]. Targeting TLR4 with antibodies or specific inhibitors has shown beneficial effects by reducing mortality in experimental models of Gram-negative sepsis [<xref ref-type="bibr" rid="CR12">12</xref>-<xref ref-type="bibr" rid="CR17">17</xref>]. Initial clinical trials also showed beneficial effects of blocking TLR4 in sepsis [<xref ref-type="bibr" rid="CR18">18</xref>], but in larger follow-up investigations, survival was not improved [<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref>]. However, the renal effects of TLR4 antagonism are incompletely investigated, and there are reasons to believe that TLR4 may be an important mediator of sepsis-induced AKI. For example, the expression of TLR4 in renal tubules, glomeruli, and peri-tubular capillaries is increased after sepsis [<xref ref-type="bibr" rid="CR21">21</xref>], and mice deficient in TLR4 have a reduced increase in blood urea nitrogen (BUN) when subjected to LPS [<xref ref-type="bibr" rid="CR22">22</xref>]. Our group recently showed that pre-treatment with TAK-242 attenuated oliguria and reduced creatinine clearance in LPS-induced hyperdynamic shock [<xref ref-type="bibr" rid="CR3">3</xref>]. However, although the aforementioned results are promising, the potential of TLR4 modulation during sepsis and septic renal failure, as well as mechanisms of action, is still largely unknown.</p><p>One of the main objectives with the current study was to investigate whether TLR4 inhibition is effective in attenuating or reversing renal dysfunction even after sepsis has developed. Therefore, TAK-242 was administered 12&#x000a0;hours into normotensive ovine sepsis caused by an intravenous live <italic>E. coli</italic> infusion, and the effect on renal function was followed for an additional 24&#x000a0;hours. To further explore the hypothesis that septic AKI is due to regional blood flow restriction, total renal blood flow and cortical and medullary microcirculation were continuously measured. Signs of ischemia were repeatedly monitored by microdialysis in the cortex and medulla. It is highly debatable whether septic AKI is associated with renal histopathology, and studies investigating structural damage to the kidney in long-term animal model of sepsis are lacking [<xref ref-type="bibr" rid="CR23">23</xref>]. Thus, both light and electron microscopy were used to analyze renal samples taken at the end of the 36-hour study period with regard to local injury and leukocyte infiltration.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><p>For detailed description of methods, please refer to the online supplemental material (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). The experiments conform to the guidelines laid out in the Guide for the Care and Use of Laboratory Animals (National Academy of Science). The Regional Ethics Committee for Experiments in Animals, Stockholm, Sweden, approved the study in advance (N285/08).</p><sec id="Sec3"><title>Surgical preparation and study protocol</title><p>Twenty-seven adult Texel crossbred ewes were included in the study. Twenty-four of these sheep were anesthetized and prepared with catheters in the right carotid artery, the pulmonary artery, and the right jugular vein. For renal hemodynamic measurements, an ultrasonic flow probe was placed around the left renal artery, and two laser Doppler flow probes, one cortical and one medullar, were sutured on the left kidney. Intrarenal metabolism was studied by microdialysis catheters in the cortex and in the medulla, respectively. A urinary retention catheter was inserted into the bladder for urine sampling. After a post-surgical recovery period of 12 to 18&#x000a0;hours, the experiments commenced with the animals being conscious and placed in a pen. Sepsis was induced by an intravenous infusion of live <italic>E. coli</italic> bacteria (bolus of 3.9&#x02009;&#x000d7;&#x02009;10<sup>9</sup> colony-forming units followed by an infusion of 6.0&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/mL colony-forming units, starting at a rate of 0.2&#x000a0;mL<bold>/</bold>hour). The infusion rate was increased stepwise every 6&#x000a0;hours until reaching 4&#x000a0;mL/hour after 30&#x000a0;hours. After 12&#x000a0;hours of sepsis, sheep were randomized to receive a bolus dose (2&#x000a0;mg/kg) followed by a continuous infusion (4&#x000a0;mg/kg per 24&#x000a0;hours) of either the selective TLR4 inhibitor TAK-242 (10&#x000a0;mg/mL) (n&#x02009;=&#x02009;7) or vehicle (n&#x02009;=&#x02009;7). The treatment was blinded to the investigators, and the content of the infusions was revealed only after the experiments were performed. To exclude that surgery per se had a major impact on the results obtained in the TAK-242 and vehicle groups, an additional sheep served as time control. This included surgical preparation and recovery and monitoring for 36&#x000a0;hours but no <italic>E. coli</italic> infusion or treatment.</p><p>To investigate whether TAK-242 had any effect on renal function per se, an additional three sheep were surgically prepared and, in a cross-over design, subjected to treatment with either TAK-242 or vehicle. The treatment was initiated by a bolus dose (2&#x000a0;mg/kg) followed by a continuous infusion (2&#x000a0;mg/kg per 12&#x000a0;hours). No <italic>E. coli</italic> was administered.</p><p>Besides the intravenous fluids given post-surgery, fluid volume support was administered as Ringer&#x02019;s Acetate solution (B. Braun Melsungen, AG, Melsungen, Germany) intravenously at 1&#x000a0;mL/kg per hour and started 6&#x000a0;hours before the infusion of live <italic>E. coli</italic> bacteria. Blood samples (approximately 20&#x000a0;mL of venous blood and 1&#x000a0;mL of arterial blood) were drawn at baseline and every 6&#x000a0;hours after commencement of sepsis. Urinary output was measured and urine samples were collected every second hour. After 36&#x000a0;hours of sepsis, animals were deeply anaesthetized with sodium thiopental and terminated by an overdose of potassium chloride. The kidney was rapidly harvested and prepared for histological evaluation. The position of the laser Doppler probes and microdialysis catheters was confirmed visually by opening the kidney post-mortem. Renal biopsies were immediately frozen and stored at &#x02212;70&#x000b0;C. If the animal was judged to be severely ill and in distress, it was euthanized prior to the end of the protocol.</p></sec><sec id="Sec4"><title>Histological evaluation of renal biopsies</title><p>Small pieces of renal tissue were prepared and evaluated by light and transmission electron microscopy. In addition, some sections were stained with anti-myeloperoxidase antibody for easy quantification of polymorphonuclear leukocyte (PMN) cells in the glomeruli, the interstitium, and the peritubular capillaries.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>Cardiovascular parameters were averaged off-line. Creatinine clearance was calculated as (urine flow&#x02009;&#x000d7;&#x02009;urine creatinine concentration)/plasma creatinine concentration. Cardiac output was indexed to body surface area (0.09&#x02009;&#x000d7;&#x02009;body weight<sup>0.67</sup>).</p><p>All statistical calculations were performed by using Statistica 8.0 (Statsoft Inc., Tulsa, OK, USA), and the graphs were created with Sigma Plot 11.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as means&#x02009;&#x000b1;&#x02009;standard deviation of the mean or as mean and 95% confidence interval. Urine production, fractional sodium excretion (FENa), and urinary-N-acetyl-beta-D-glucosaminidase (U-NAG) values were transformed to follow a normal distribution by taking the logarithm of the raw data. Changes in parameters over time were analyzed according to a two-way repeated measures analysis of variance (ANOVA), with time as within effects and treatment (control/TAK-242) as between effects. If there was a significant interaction between time&#x02009;&#x000d7;&#x02009;treatment, an additional one-way repeated measures ANOVA was performed for each treatment to investigate whether that group changed significantly over time. The result of this analysis is not displayed in the figures but is referred to in the Results section. The significance level was set at a <italic>P</italic> value of not more than 0.05. Mann-Whitney <italic>U</italic> test was used to evaluate difference in PMN count and histological scores between treatments.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><p>Nine out of twenty-three sheep subjected to <italic>E. coli</italic> had to be euthanized before completion of the protocol: five before treatment was started as well as two TAK-242-treated animals and two vehicle-treated animals between 12 and 14&#x000a0;hours of sepsis. These sheep are not included in the data presented in the figures/tables or the statistical analyses. No effect of surgery per se was seen in the sheep that was sham-operated (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S3).</p><sec id="Sec7"><title><italic>E. coli</italic> infusion caused hyperdynamic sepsis</title><p>Intravenous infusion of live <italic>E. coli</italic> bacteria caused classic signs of hyperdynamic sepsis; tachycardia, pulmonary hypertension, increased cardiac index, and a decrease in systemic vascular resistance (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A-C and F, <italic>P</italic> &#x0003c;0.05 for all). However, mean arterial blood pressure remained close to baseline levels, indicating that the animals were not in shock (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E). TAK-242 attenuated the increase in mean pulmonary arterial pressure (MPAP) but had no significant effect on any other of these variables (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Arterial levels of lactate increased as a response to sepsis. However, in parallel with an improved renal function, TAK-242 reversed this trend and reduced lactate levels to near baseline values (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D). Treatment with TAK-242 attenuated the decline in arterial partial pressure of oxygen (pO<sub>2</sub>) caused by sepsis and it ended significantly higher compared with the control group. Partial pressure of carbon dioxide (pCO<sub>2</sub>) increased in both groups without intergroup difference. No significant change over time or difference between the groups was observed in arterial pH, base excess, hematocrite, plasma protein, sodium, or potassium levels (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S1). Sepsis induced nitric oxide (NO) formation as indicated by increased plasma levels of NOx (sum of nitrite and nitrate) and cyclic guanosine monophosphate (<italic>P</italic> &#x0003c;0.05 for both) with no effect of treatment with TAK-242. NOx in urine did not change significantly during the experiment (Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S1).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Changes in cardiac index (A), heart rate (B), mean pulmonary arterial pressure (MPAP) (C), arterial lactate (D), mean arterial blood pressure (MAP) (E), and systemic vascular resistance (SVR) (F) in response to sepsis and treatment with either the selective TLR4 inhibitor TAK-242 (n&#x02009;=&#x02009;7) or vehicle (n&#x02009;=&#x02009;7).</bold> Data are expressed as mean and 95% confidence interval. Asterisk indicates a significant difference between TAK-242 and control in response to sepsis. Analysis of variance (ANOVA) repeated measures from 12 to 36&#x000a0;hours.</p></caption><graphic xlink:href="13054_2014_488_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec8"><title>Sepsis-induced renal dysfunction was reversed by the TLR4 inhibitor TAK-242</title><p>After 12&#x000a0;hours of sepsis, renal function was reduced as measured by elevated plasma levels of creatinine and BUN, together with a decrease in creatinine clearance, urine production, and filtration fraction (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A-E, <italic>P</italic> &#x0003c;0.05 for all). The TLR4 inhibitor had a clear beneficial effect on renal function: Urine production decreased progressively in the control group, reaching severe oliguria in all animals, but TAK-242 not only prevented this decline but also improved diuresis significantly between 12 and 36&#x000a0;hours (<italic>P</italic> &#x0003c;0.01, Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). Furthermore, treatment with TAK-242 abolished the impairment in creatinine clearance (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, <italic>P</italic>&#x02009;=&#x02009;0.002) and attenuated the increase in plasma levels of creatinine, filtration fraction, and BUN (<italic>P</italic> &#x0003c;0.05, for all Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). U-NAG, a marker of tubular damage, was significantly elevated at the end of the experiment, but TAK-242 attenuated this increase (<italic>P</italic> &#x0003c;0.05, Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F), indicating less tubular injury in sheep with TLR4 inhibition.<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Changes in diuresis (A), creatinine clearance (Crea Clear) (B), filtration fraction (C), blood urea nitrogen (BUN) (D) plasma creatinine (P-Crea) (E), and urinary concentrations of N-acetyl-&#x000df;-D-glucosaminidase (U-NAG) (F) in response to sepsis and treatment with either the selective TLR4 inhibitor TAK-242 (n&#x02009;=&#x02009;7) or vehicle (n&#x02009;=&#x02009;7).</bold> Data are expressed as mean and 95% confidence interval. Asterisk indicates a significant difference between TAK-242 and control in response to sepsis. Analysis of variance (ANOVA) repeated measures from 12 to 36&#x000a0;hours.</p></caption><graphic xlink:href="13054_2014_488_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec9"><title>Sepsis did not cause renal hypoperfusion</title><p>A possible explanation for the beneficial effects of TAK-242 was prevention of renal hypoperfusion. However, renal artery blood flow increased (<italic>P</italic> &#x0003c;0.001) during sepsis and renal vascular resistance was significantly decreased (<italic>P</italic> &#x0003c;0.001) without any intergroup differences (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). This was mirrored as an increased perfusion in the renal cortex (<italic>P</italic> &#x0003c;0.05), but medullary perfusion remained close to baseline levels in both groups (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Light microscopy revealed no obvious renal tubular damage that explained the renal dysfunction. The tubules appeared normal except in two of the vehicle animals, where areas of proximal tubular injury were seen within the cortex (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). In such areas, the epithelial cells showed pyknotic or disintegrated nuclei (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D) or isometric vacuolization of the cytoplasm or both. In one of the TAK-242-treated animals, similar but much milder changes were seen. No changes were seen in larger vessels. In two of the vehicle animals, fibrin thrombi were found in the glomerular capillaries (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S1).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Changes in renal artery blood flow (RBF) (A), laser Doppler changes in renal cortex (LD Cortex) (B), laser Doppler changes in renal medulla (LD Medulla) (C), renal vascular resistance (RVR) (D), lactate/pyruvate ratio in cortex (L/P Cortex) (E), and lactate/pyruvate ratio in medulla (L/P Medulla) (F) in response to sepsis and treatment with either the selective TLR4 inhibitor TAK-242 (n&#x02009;=&#x02009;7) or vehicle (n&#x02009;=&#x02009;7).</bold> Data are expressed as mean and 95% confidence interval. Asterisk indicates a significant difference between TAK-242 and control in response to sepsis. Analysis of variance (ANOVA) repeated measures from 12 to 36&#x000a0;hours.</p></caption><graphic xlink:href="13054_2014_488_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Increased renal neutrophil infiltration is attenuated by TLR4 inhibition.</bold> Light microscopy with hematoxylin/eosin staining shows an increased number of polymorphonuclear leukocytes (PMNs) (arrows) in the glomeruli and within the interstitium/peritubular capillaries in both vehicle-treated <bold>(C)</bold> and TAK-242-treated <bold>(B)</bold> animals in comparison with sham <bold>(A)</bold>. Tubular epithelial injury was seen with pyknotic and disintegrated nuclei in two of the vehicle-treated animals&#x02014;<bold>(C)</bold> white arrow and <bold>(D)</bold> arrows&#x02014;and one of the TAK-242-treated animals.</p></caption><graphic xlink:href="13054_2014_488_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec10"><title>Treatment with a TLR4 inhibitor attenuated septic renal hyperlactemia</title><p>To measure renal metabolic changes, microdialysis probes were placed in the renal cortex and medulla. During the first 12&#x000a0;hours of sepsis lactate, pyruvate and the lactate/pyruvate (L/P) ratio increased in both the cortex and the medulla whereas glucose was not significantly altered (Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Table S2). TAK-242 significantly attenuated the increase in lactate (Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Table S2) and reduced the L/P ratio (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) in both cortex and medulla. However, glucose and pyruvate levels remained stable, and no effect of treatment was observed (Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Table S2).</p></sec><sec id="Sec11"><title>Treatment with a TLR4 inhibitor reduced renal neutrophil infiltration</title><p>In the vehicle- and TAK-242-treated groups, increased amounts of PMN cells were found in the glomeruli and the interstitium/peritubular capillaries compared with controls. This was confirmed by quantification of PMNs by using immunohistochemistry (Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Compared with vehicle, TAK-242 significantly reduced the number of PMNs in the interstitium (<italic>P</italic>&#x02009;=&#x02009;0.01, Figure&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A) but not in the glomerulus (<italic>P</italic>&#x02009;=&#x02009;0.16, Figure&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>B).<fig id="Fig5"><label>Figure 5</label><caption><p>
<bold>Immunohistochemistry with anti-myeloperoxidase antibodies show increased number of polymorphonuclear leukocytes (PMNs) in glomerular capillaries (G) and interstitium/peritubular capillaries (arrow) in vehicle-treated (B) and TAK-242-treated (C) group in comparison with sham (A).</bold>
</p></caption><graphic xlink:href="13054_2014_488_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Figure 6</label><caption><p>
<bold>Number of polymorphonuclear leukocytes (PMNs) in interstitium (A) and glomerulus (B) as well as histological determination of endothelial swelling (C) and degree of fenestration in vehicle-treated (D) (n&#x02009;=&#x02009;7) and TAK-242-treated (n&#x02009;=&#x02009;7) animals.</bold> Zero indicates no swelling/decreased fenestration, 1 indicates some swelling/decreased fenestration, and 2 indicates severe swelling/decreased fenestration as determined by electron microscopy. Data are expressed as raw numbers. <italic>P</italic> &#x0003c;0.05 is considered significant.</p></caption><graphic xlink:href="13054_2014_488_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec12"><title>Sepsis-induced endothelial swelling and decreased fenestration in the glomeruli were attenuated by a TLR4 inhibitor</title><p>To examine the glomerular effects of sepsis and subsequent treatment with a TLR4 inhibitor, electron microscopy was used. There was no difference in the degree of foot process effacement or in the thickness of the glomerular basement membrane (GBM) between the vehicle-treated (232&#x02009;&#x000b1;&#x02009;29&#x000a0;nm), TAK-242-treated (264&#x02009;&#x000b1;&#x02009;72&#x000a0;nm), and sham (242&#x02009;&#x000b1;&#x02009;9&#x000a0;nm) groups (Figure&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). However, there was a difference in the ultrastructure of the endothelial cells in the glomerular capillaries. The endothelial cells of the vehicle-treated animals were more swollen (<italic>P</italic>&#x02009;=&#x02009;0.03, Figures&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C and <xref rid="Fig7" ref-type="fig">7</xref>) and showed a tendency for decreased fenestration (<italic>P</italic>&#x02009;=&#x02009;0.07, Figures&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>D and <xref rid="Fig7" ref-type="fig">7</xref>) compared with TAK-242-treated animals and sham. Furthermore, the light microscopic observation of fibrin thrombi was confirmed in the two vehicle-treated animals (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S1).<fig id="Fig7"><label>Figure 7</label><caption><p>
<bold>Electron microscopic images of the glomerular capillaries in sham (A), vehicle-treated (B), and TAK-242-treated (C) animals.</bold> The same images magnified showing glomerular capillaries in sham <bold>(D)</bold>, vehicle-treated <bold>(E)</bold>, and TAK-242-treated <bold>(F)</bold> animals. Asterisk indicates endothelial cell swelling, and arrowheads show decreased fenestration of the glomerular endothelium. Bars = 2 &#x003bc;m <bold>(A, B, C)</bold> and 1 &#x003bc;m <bold>(D, E, F)</bold>.</p></caption><graphic xlink:href="13054_2014_488_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec13"><title>TAK-242 had no effect per se</title><p>There were no obvious differences in MAP, HR, CI, or MPAP between TAK-242 and vehicle during the 12-hour treatment period in healthy sheep (Additional file <xref rid="MOESM6" ref-type="media">6</xref>: Figure S2). Renal function, as evaluated by creatinine clearance, plasma clearance, BUN, and urine output, remained stable, and no difference between treatments was seen (Additional file <xref rid="MOESM7" ref-type="media">7</xref>: Figure S3). Finally, renal blood flow and blood gas parameters remained unaffected by TAK-242 per se (Additional file <xref rid="MOESM7" ref-type="media">7</xref>: Figure S3 and Additional file <xref rid="MOESM8" ref-type="media">8</xref>: Table S4).</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>In the present study, we aimed to investigate the renal effects of a TLR4-inhbitor, TAK-242, in experimental sepsis. The most striking finding was that TAK-242 reversed a progressive decline in renal function when administered therapeutically after 12&#x000a0;hours of hyperdynamic <italic>E. coli</italic> sepsis. This was associated with a prominent reduction in renal neutrophil infiltration, a decreased swelling of the endothelium in the glomerular capillaries, an attenuation of arterial and renal hyperlactemia, and less tubular damage as indicated by reduced U-NAG. Furthermore, no major effects on systemic or local renal hemodynamics by TAK-242 were seen during sepsis, and in separate experiments in animals without sepsis, TAK-242 had no obvious major effects per se.</p><p>Proper animal models of septic AKI are difficult to achieve, and too often they do not mimic the clinical scenario [<xref ref-type="bibr" rid="CR24">24</xref>]. In this study, we used fluid-resuscitated, conscious animals developing severe hyperdynamic sepsis caused by live bacteria. Detailed renal functional data were collected repeatedly over an extended time period and related to immune function and histological pathology. In addition, treatment was started when sepsis and renal dysfunction were already present. Another strength of this investigation was that the renal histological findings in large mimicked what was recently described in human kidney after sepsis [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Innate immunity is the first line of defense against invading microbes and is crucial for preventing infections. TLR4 is central in this immune activation by binding LPS [<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR25">25</xref>], which results in an inflammatory response that induces the production and release of cytokines as well as stimulation of inflammatory cells [<xref ref-type="bibr" rid="CR11">11</xref>]. Among these cells are neutrophils, which are activated and stimulated to transmigrate from blood to tissue. This is caused by TLR4-mediated release of interleukin-1B (IL-1B), tumor necrosis factor-alpha (TNF&#x003b1;), and IL-6. Another important neutrophil activator released by TLR4 stimulation is serum amyloid protein 3, which mediates its effect by targeting the formyl peptide receptor [<xref ref-type="bibr" rid="CR26">26</xref>]. Although the inflammatory response is crucial for preventing infections, a strong activation of the innate immune system, like in sepsis, may inflict damage to endogenous tissue and impair organ function. TAK-242 binds selectively to the intracellular domain of TLR4 and disrupts the interaction with several adaptor molecules. This leads to inhibition of both the MyD88-dependent and the TRIF (TIR domain-containing adapter-inducing IFN-&#x003b2;)-dependent pathway for TLR4 signal transduction [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>Acute tubular necrosis (ATN) caused by ischemia has been assumed to be the underlying pathophysiology of septic AKI [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR28">28</xref>]. Massive release of NO is believed to cause vasodilation that result in relative hypovolemia, a reduction in cardiac output, and hypotension. As a reflex, renal sympathetic nerve activity is increased together with elevated levels of vasopressin, endothelin, angiotensin II, and aldosterone. The resulting renal vascular vasoconstriction leads to ischemia and subsequent ATN that impairs renal function. Undoubtedly, ischemia is a crucial factor for many types of AKI. However, in sepsis, the situation may sometimes be different. Most patients with sepsis present with a hyperdynamic circulation with elevated cardiac output [<xref ref-type="bibr" rid="CR29">29</xref>]. Experimental data indicate that AKI develops although total renal blood flow is increased [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR23">23</xref>] and hypotension is counteracted by vasoactive drugs [<xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, the correlation between ATN and septic renal failure is weak in both human and animal studies [<xref ref-type="bibr" rid="CR30">30</xref>]. The current results obtained in normotensive septic sheep confirm that hypotension is not a necessary attribute for septic AKI. This is in line with studies in critically ill patients with severe sepsis, in whom blood pressure levels did not correlate with the severity of renal failure [<xref ref-type="bibr" rid="CR31">31</xref>]. TAK-242 drastically improved renal function without major hemodynamic effects. Moreover, there was no sign of renal vasoconstriction, as total renal artery blood flow as well as cortical and medullary perfusion did not decline during the 36-hour experiment. Thus, renal hypoperfusion appears highly unlikely as a cause of septic AKI, given this experimental setting. A recently promoted hypothesis for sepsis-induced AKI is that the inflammatory response causes a preferential dilatation of renal efferent arterioles, increasing renal blood flow but reducing the hydrostatic pressure for glomerular filtration and thereby glomerular filtration rate (GFR) [<xref ref-type="bibr" rid="CR32">32</xref>]. The most important vasodilator released in sepsis is NO, and it has been suggested that excessive intra-renal NO could be responsible for the reduction in post-glomerular resistance [<xref ref-type="bibr" rid="CR33">33</xref>]. However, it is unlikely that the effect of TLR4 inhibition on renal function in this study is mediated by reduced NO formation as there were no differences in either MAP or renal blood flow and as TAK-242 did not affect NOx or cyclic guanosine monophosphate (cGMP) levels. This view is supported by results demonstrating no effect on renal function after intrarenal NO synthase inhibition during Gram-negative sepsis [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>Both cortical and medullary ratios of L/P were significantly increased by sepsis but subsequently reduced by TAK-242. In view of the preserved renal circulation, the renal hyperlactemia cannot easily be explained by reduced renal oxygen supply. However, direct measurement of renal tissue oxygenation or the utilization of oxygen by renal mitochondria was not performed in this study. Elevated lactate levels in sepsis not related to hypoxia have been linked to stimulation of muscle Na/K-ATPase [<xref ref-type="bibr" rid="CR34">34</xref>] and mitochondrial dysfunction [<xref ref-type="bibr" rid="CR35">35</xref>]. Thus, besides hypoxia, other factors may explain the renal hyperlactemia.</p><p>Sepsis caused severe endothelial swelling and decreased glomerular fenestration, both of which were reduced by TLR4 inhibition. The renal dysfunction observed may, to a large extent, be a consequence of decreased glomerular filtration per se, as creatinine clearance and the filtration fraction decreased significantly in the vehicle-treated animals, without significant tubular damage. Endothelial dysfunction in the peritubular capillaries has been highlighted as an important injury pathway in septic AKI [<xref ref-type="bibr" rid="CR36">36</xref>], possibly by inducing ATN [<xref ref-type="bibr" rid="CR37">37</xref>]. Herein, U-NAG did increase in vehicle-treated animals as a possible sign of tubular injury, but this took place several hours after renal function started to decline and was not confirmed by light microscopy. Instead, it is possible that endothelial swelling and perhaps decreased fenestration in the glomerulus may play an important role in the injury pathway and propagation of septic AKI. However, an early and specific marker of glomerular membrane dysfunction is urine protein leakage, and this was not detected in this study and is not a hallmark of sepsis-induced AKI.</p><p>Mobilization and recruitment of PMNs by the innate immune defense constitute a key event in response to an infection. After extravasation, PMNs destroy invading organisms by phagocytosis, release of acid hydrolases and antimicrobial peptides, and stimulation of antibiotic actions of monocytes and macrophages [<xref ref-type="bibr" rid="CR38">38</xref>]. However, PMN degranulation may also inflict damage to endogenous tissue. The role of PMNs in septic AKI is largely unknown, but after renal ischemia and reperfusion, PMNs have been shown to transmigrate from the circulation and contribute to AKI [<xref ref-type="bibr" rid="CR39">39</xref>]. In sepsis, Castoldi and colleagues [<xref ref-type="bibr" rid="CR40">40</xref>] recently showed that TLR4-deficient mice had reduced renal neutrophil activation and infiltration compared with wild-type mice and that neutrophil depletion improved renal function. This indicates that the extensive renal neutrophil accumulation caused by sepsis in this study is potentially deleterious. Activation of renal endothelial TLR4 has been suggested to play a critical role in the upregulation of adhesion molecules which can promote the recruitment of leukocytes to areas of injury and aggravate damage and inflammation in the tissue [<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref>]. A TLR4-dependent pathway promoting renal injury and inflammation in antibody-mediated glomeruli-nephritis and cisplatin-induced nephrotoxicity has also been described [<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref>]. Therefore, reduced TLR4-dependent infiltration of PMNs may have contributed to the improved renal function in the TAK-242 group. This is supported by recent findings of substantial renal leukocyte infiltration in human septic shock [<xref ref-type="bibr" rid="CR6">6</xref>]. Possible mechanisms for the renal dysfunction include PMN vascular endothelial attachment that reduces blood flow and causes ischemia [<xref ref-type="bibr" rid="CR45">45</xref>] or tubular damage by migrated PMNs [<xref ref-type="bibr" rid="CR46">46</xref>]. However, as discussed previously, no rheological effects of sepsis or TLR4 inhibition were noted in the current study, and light microscopy revealed no convincing evidence of general or widely spread structural damage to the tubules. Taken together, these observations indicate that neutrophil activation and recruitment into the kidney are potential and perhaps crucial mediators of septic AKI, although the underlying mechanism remains unknown. As shown in a series of elegant experiments by Watts and colleagues [<xref ref-type="bibr" rid="CR47">47</xref>-<xref ref-type="bibr" rid="CR49">49</xref>], TLR4 activation may also affect renal function by impairing tubular transport. In particular, HCO<sub>3</sub><sup>&#x02212;</sup> reabsorption is inhibited by the direct effect of LPS on TLR4, and this may contribute to sepsis-induced acidosis.</p><p>Besides renal effects, TLR4 inhibition significantly attenuated the increase in mean pulmonary artery pressure and prevented the decrease in partial pressure of oxygen. The mechanism for these findings is unknown. However, a TLR4-dependent pathway for recruitment of neutrophils into the lung has been highlighted in endotoxemic mice [<xref ref-type="bibr" rid="CR41">41</xref>], and PMN degranulation may cause severe lung damage [<xref ref-type="bibr" rid="CR38">38</xref>]. The reason why arterial pCO<sub>2</sub> did not change is unknown but may be related to the fact that CO<sub>2</sub>, compared with oxygen, more easily diffuses between blood and alveolus.</p><p>The current results are partly in contrast to the recent clinical trial using a TLR4 antagonist in sepsis [<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref>]. In that study, no effect on survival was discovered. However, data on renal function were not reported, and only a minority of the patients had verified Gram-negative sepsis. Thus, it is possible that some patients with sepsis would still benefit from TLR4 inhibition.</p><p>We would like to acknowledge some of the limitations of this study. Evaluation of the renal microcirculation was performed with the use of laser Doppler probes surgically implanted in both the cortex and medulla. This is a well-established method and is frequently used for assessment of renal tissue perfusion; however, the technique is invasive, and measurements are performed at a small proportion of the kidney, less than approximately 1&#x000a0;mm<sup>3</sup> at each probe site. Although the technique is a good option for continuous data acquisition [<xref ref-type="bibr" rid="CR50">50</xref>], it has problems detecting heterogeneity in microvascular flow. The use of creatinine clearance as an indicator for GFR is often used in the clinical setting, but the accuracy is limited in patients. However, in sheep, renal clearance of endogenous creatinine may be a relatively adequate measure of GFR [<xref ref-type="bibr" rid="CR51">51</xref>].</p></sec><sec id="Sec15" sec-type="conclusion"><title>Conclusions</title><p>In summary, our data show that TLR4 signaling is important for the development of septic AKI and that treatment with a TLR4 inhibitor is able to reverse a manifest reduction in renal function caused by sepsis. Although further studies are necessary, this suggests that targeting TLR4 may be a potential way to treat AKI caused by Gram-negative sepsis. Furthermore, in the present model, septic AKI is not due to hypoperfusion-induced ischemia but rather an inflammatory reaction within the kidney reducing glomerular filtration. Endothelial swelling in the glomerulus may be a contributing factor for the latter.</p></sec><sec id="Sec16"><title>Key messages</title><p><list list-type="bullet"><list-item><p>Inhibiting Toll-like receptor 4 reverses a manifest renal dysfunction caused by <italic>E. coli</italic> sepsis.</p></list-item><list-item><p>In the present model, septic acute kidney injury is not due to hypoperfusion-induced ischemia but rather an inflammatory reaction within the kidney.</p></list-item><list-item><p>Endothelial swelling in the glomerulus may be a contributing factor for the reduced glomerular filtration.</p></list-item><list-item><p>Toll-like receptor 4 antagonism has no obvious effects on renal function in healthy individuals.</p></list-item></list></p></sec></body><back><app-group><app id="App1"><sec id="Sec17"><title>Additional files</title><p><media position="anchor" xlink:href="13054_2014_488_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1:</label><caption><p>
<bold>Detailed Materials and Methods.</bold> A more extensive description of materials and methods.</p></caption></media><media position="anchor" xlink:href="13054_2014_488_MOESM2_ESM.pdf" id="MOESM2"><label>Additional file 2: Table S3.</label><caption><p>Sham-operated animal without sepsis. Data are for sham animal without sepsis (n&#x02009;=&#x02009;1) and expressed as raw data from baseline to 36&#x000a0;hours. CI, cardiac index; cort, cortex; Crea clearance, creatinine clearance; HR, heart rate; Lactate<sub>art</sub>, arterial levels of lactate; LD, laser Doppler; L/P, Lactate/Pyruvate ratio; MAP, mean arterial pressure; med, medulla; MD, microdialysis; MPAP, mean pulmonary arterial pressure; pCO<sub>2</sub>, partial pressure of carbon dioxide; pO<sub>2</sub>, partial pressure of oxygen; P-Protein, plasma protein; RBF, renal blood flow.</p></caption></media><media position="anchor" xlink:href="13054_2014_488_MOESM3_ESM.pdf" id="MOESM3"><label>Additional file 3: Table S1.</label><caption><p>Systemic variables. Data are for TAK-242 and control expressed as mean and standard deviation (SD). Asterisk indicates a significant difference between TAK-242 and control in response to sepsis. Analysis of variance (ANOVA) repeated measures, including 12, 18, 24, 30, and 36&#x000a0;hours. Differences were considered significant at <italic>P</italic> &#x02264;0.05. cGMP, cyclic guanosine monophosphate; NOx, the sum of nitrite and nitrate concentration; pCO<sub>2</sub>, partial pressure of carbon dioxide; pO<sub>2</sub>, partial pressure of oxygen; p-protein, plasma protein.</p></caption></media><media position="anchor" xlink:href="13054_2014_488_MOESM4_ESM.pdf" id="MOESM4"><label>Additional file 4: Figure S1.</label><caption><p>Fibrin thrombi formation in glomerular capillaries. Fibrin thrombi formation in glomerular capillaries. In two of the vehicle-treated animals, fibrin thrombi (arrow) were seen both in light microscopy with Ladewig staining (a) and in electron microscopy (b).</p></caption></media><media position="anchor" xlink:href="13054_2014_488_MOESM5_ESM.pdf" id="MOESM5"><label>Additional file 5: Table S2.</label><caption><p>Microdialysis in renal cortex and medulla. Data are for TAK-242 and control expressed as mean and standard deviation (SD). Asterisk indicates a significant difference between TAK-242 and control in response to sepsis. Analysis of variance (ANOVA) repeated measures, including 12, 18, 24, 30, and 36&#x000a0;hours. Differences were considered significant at <italic>P</italic> &#x02264;0.05. cort, cortex; MD, microdialysis; med, medulla.</p></caption></media><media position="anchor" xlink:href="13054_2014_488_MOESM6_ESM.pdf" id="MOESM6"><label>Additional file 6: Figure S2.</label><caption><p>Changes in heart rate (A), cardiac index (B), mean pulmonary artery pressure (MPAP) (C), and mean arterial pressure (MAP) (D) in response to treatment with either the selective TLR4 inhibitor TAK-242 (filled symbols) or vehicle (open symbols). N&#x02009;=&#x02009;3 in a cross-over design. Data are shown for each individual animal.</p></caption></media><media position="anchor" xlink:href="13054_2014_488_MOESM7_ESM.pdf" id="MOESM7"><label>Additional file 7: Figure S3.</label><caption><p>Changes in creatinine clearance (A), P-creatinine (B), blood urea nitrogen (BUN) (C), renal blood flow (D), and urine output (E) in response to treatment with either the selective TLR4 inhibitor TAK-242 (filled symbols) or vehicle (open symbols). N&#x02009;=&#x02009;3 in a cross-over design. Data are shown for each individual animal.</p></caption></media><media position="anchor" xlink:href="13054_2014_488_MOESM8_ESM.pdf" id="MOESM8"><label>Additional file 8: Table S4.</label><caption><p>Sheep without sepsis treated with TAK-242. Blood gas data for three healthy sheep receiving TAK-242 or vehicle for 12&#x000a0;hours in a cross-over design.</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>AKI</term><def><p>acute kidney injury</p></def></def-item><def-item><term>ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term>ATN</term><def><p>acute tubular necrosis</p></def></def-item><def-item><term>BUN</term><def><p>blood urea nitrogen</p></def></def-item><def-item><term>CI</term><def><p>cardiac index</p></def></def-item><def-item><term>GBM</term><def><p>glomerular basement membrane</p></def></def-item><def-item><term>GFR</term><def><p>glomerular filtration rate</p></def></def-item><def-item><term>HR</term><def><p>heart rate</p></def></def-item><def-item><term>L/P</term><def><p>lactate/pyruvate</p></def></def-item><def-item><term>LPS</term><def><p>lipopolysaccharide</p></def></def-item><def-item><term>MAP</term><def><p>mean arterial blood pressure</p></def></def-item><def-item><term>MPAP</term><def><p>mean pulmonary arterial blood pressure</p></def></def-item><def-item><term>NAG</term><def><p>N-acetyl-beta-D-glucosaminidas</p></def></def-item><def-item><term>NO</term><def><p>nitric oxide</p></def></def-item><def-item><term>NOx</term><def><p>sum of nitrite and nitrate</p></def></def-item><def-item><term>pCO<sub>2</sub></term><def><p>partial pressure of carbon dioxide</p></def></def-item><def-item><term>PMN</term><def><p>polymorphonuclear leukocyte</p></def></def-item><def-item><term>TLR4</term><def><p>Toll-like receptor 4</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>JoF conceived and designed the study, carried out the animal experiments, participated in the analyses of biological samples, performed the statistical analyses, and drafted the manuscript. MR carried out the animal experiments and participated in the analyses of biological samples. KH performed the electron microscopy investigation and participated in the analyses of data. JaF, MT, and SE participated in the animal experiments and contributed in drafting the manuscript. EK performed analyses of biological samples. EW contributed to the data analyses and analyzed biological samples. VO helped to design the study and supplied the bacteria to induce sepsis. AW performed the histology and participated in the analyses of data. RF conceived and designed the study, carried out the animal experiments, participated in the analyses of biological samples, and drafted the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><p>We are most grateful for the excellent laboratory assistance by Azar Baharpoor and Carina Nihlen, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm. Takeda Pharmaceutical Company Limited (Osaka, Japan) kindly provided us with TAK-242. The study was supported by funds from the Swedish Research Council (grant 521-2011-2843, RF), Karolinska University Hospital (JoF, JaF, AW, KH, AW, and VO), Karolinska Institutet (MR and SE), The Lars Hierta Foundation (JoF), The Swedish Society of Medicine (RF), The Swedish Society for Anaesthesia and Intensive Care (JoF), The Ruth and Richard Juhlin Foundation (RF), The &#x000c5;ke Wiberg Foundation (RF), and The Swedish Kidney Association (JoF). There was no involvement of the funding resources in research design collection, analysis, and interpretation of data. The writing and publication of the manuscript were done by the authors without any participation or influence from the funding sources for any of the authors.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugan</surname><given-names>R</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name></person-group><article-title>Acute kidney injury: what&#x02019;s the prognosis?</article-title><source>Nat Rev Nephrol</source><year>2011</year><volume>7</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2011.13</pub-id><pub-id pub-id-type="pmid">21343898</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrier</surname><given-names>RW</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Acute renal failure and sepsis</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1056/NEJMra032401</pub-id><pub-id pub-id-type="pmid">15247356</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenhammar</surname><given-names>J</given-names></name><name><surname>Rundgren</surname><given-names>M</given-names></name><name><surname>Forestier</surname><given-names>J</given-names></name><name><surname>Kalman</surname><given-names>S</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name><name><surname>Frithiof</surname><given-names>R</given-names></name></person-group><article-title>Toll-like receptor 4 inhibitor TAK-242 attenuates acute kidney injury in endotoxemic sheep</article-title><source>Anesthesiology</source><year>2011</year><volume>114</volume><fpage>1130</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e31820b8b44</pub-id><pub-id pub-id-type="pmid">21394006</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frithiof</surname><given-names>R</given-names></name><name><surname>Soehnlein</surname><given-names>O</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name><name><surname>Fenhammar</surname><given-names>J</given-names></name><name><surname>Hjelmqvist</surname><given-names>H</given-names></name><name><surname>Lindbom</surname><given-names>L</given-names></name><name><surname>Rundgren</surname><given-names>M</given-names></name></person-group><article-title>The effects of isoflurane anesthesia and mechanical ventilation on renal function during endotoxemia</article-title><source>Acta Anaesthesiol Scand</source><year>2011</year><volume>55</volume><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2011.02406.x</pub-id><pub-id pub-id-type="pmid">21391922</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>May</surname><given-names>CN</given-names></name></person-group><article-title>The impact of intrarenal nitric oxide synthase inhibition on renal blood flow and function in mild and severe hyperdynamic sepsis</article-title><source>Crit Care Med</source><year>2011</year><volume>39</volume><fpage>770</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318206c1fb</pub-id><pub-id pub-id-type="pmid">21169816</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerolle</surname><given-names>N</given-names></name><name><surname>Nochy</surname><given-names>D</given-names></name><name><surname>Guerot</surname><given-names>E</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Fagon</surname><given-names>JY</given-names></name><name><surname>Diehl</surname><given-names>JL</given-names></name><name><surname>Hill</surname><given-names>G</given-names></name></person-group><article-title>Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><fpage>471</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1723-x</pub-id><pub-id pub-id-type="pmid">19924395</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Preston-Hurlburt</surname><given-names>P</given-names></name><name><surname>Janeway</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group><article-title>A human homologue of the Drosophila Toll protein signals activation of adaptive immunity</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>394</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1038/41131</pub-id><pub-id pub-id-type="pmid">9237759</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshino</surname><given-names>K</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Sanjo</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>3749</fpage><lpage>3752</lpage><pub-id pub-id-type="pmid">10201887</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poltorak</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Smirnova</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>MY</given-names></name><name><surname>Van Huffel</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Birdwell</surname><given-names>D</given-names></name><name><surname>Alejos</surname><given-names>E</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Galanos</surname><given-names>C</given-names></name><name><surname>Freudenberg</surname><given-names>M</given-names></name><name><surname>Ricciardi-Castagnoli</surname><given-names>P</given-names></name><name><surname>Layton</surname><given-names>B</given-names></name><name><surname>Beutler</surname><given-names>B</given-names></name></person-group><article-title>Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene</article-title><source>Science</source><year>1998</year><volume>282</volume><fpage>2085</fpage><lpage>2088</lpage><pub-id pub-id-type="doi">10.1126/science.282.5396.2085</pub-id><pub-id pub-id-type="pmid">9851930</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>ST</given-names></name><name><surname>Lariviere</surname><given-names>L</given-names></name><name><surname>Leveque</surname><given-names>G</given-names></name><name><surname>Clermont</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>KJ</given-names></name><name><surname>Gros</surname><given-names>P</given-names></name><name><surname>Malo</surname><given-names>D</given-names></name></person-group><article-title>Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4)</article-title><source>J Exp Med</source><year>1999</year><volume>189</volume><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1084/jem.189.4.615</pub-id><pub-id pub-id-type="pmid">9989976</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>TLR signaling</article-title><source>Semin Immunol</source><year>2007</year><volume>19</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2006.12.004</pub-id><pub-id pub-id-type="pmid">17275323</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daubeuf</surname><given-names>B</given-names></name><name><surname>Mathison</surname><given-names>J</given-names></name><name><surname>Spiller</surname><given-names>S</given-names></name><name><surname>Hugues</surname><given-names>S</given-names></name><name><surname>Herren</surname><given-names>S</given-names></name><name><surname>Ferlin</surname><given-names>W</given-names></name><name><surname>Kosco-Vilbois</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>H</given-names></name><name><surname>Kirschning</surname><given-names>CJ</given-names></name><name><surname>Ulevitch</surname><given-names>R</given-names></name><name><surname>Elson</surname><given-names>G</given-names></name></person-group><article-title>TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>6107</fpage><lpage>6114</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.9.6107</pub-id><pub-id pub-id-type="pmid">17947685</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldfarb</surname><given-names>RD</given-names></name><name><surname>Ortegel</surname><given-names>JW</given-names></name><name><surname>Parrillo</surname><given-names>JE</given-names></name><name><surname>Zanotti-Cavazzoni</surname><given-names>S</given-names></name><name><surname>Casey</surname><given-names>LC</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name></person-group><article-title>TAKEDA-143242 increased survival via reduced cytokines in porcine peritonitis</article-title><source>J Surg Res</source><year>2011</year><volume>166</volume><fpage>e165</fpage><lpage>e173</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2010.09.031</pub-id><pub-id pub-id-type="pmid">21236445</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuno</surname><given-names>M</given-names></name><name><surname>Nemoto</surname><given-names>K</given-names></name><name><surname>Ninomiya</surname><given-names>N</given-names></name><name><surname>Inagaki</surname><given-names>E</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><article-title>The novel selective toll-like receptor 4 signal transduction inhibitor tak-242 prevents endotoxaemia in conscious Guinea-pigs</article-title><source>Clin Exp Pharmacol Physiol</source><year>2009</year><volume>36</volume><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2008.05121.x</pub-id><pub-id pub-id-type="pmid">19673945</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roger</surname><given-names>T</given-names></name><name><surname>Froidevaux</surname><given-names>C</given-names></name><name><surname>Le Roy</surname><given-names>D</given-names></name><name><surname>Reymond</surname><given-names>MK</given-names></name><name><surname>Chanson</surname><given-names>AL</given-names></name><name><surname>Mauri</surname><given-names>D</given-names></name><name><surname>Burns</surname><given-names>K</given-names></name><name><surname>Riederer</surname><given-names>BM</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Calandra</surname><given-names>T</given-names></name></person-group><article-title>Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><fpage>2348</fpage><lpage>2352</lpage><pub-id pub-id-type="doi">10.1073/pnas.0808146106</pub-id><pub-id pub-id-type="pmid">19181857</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>T</given-names></name><name><surname>Sunamoto</surname><given-names>M</given-names></name><name><surname>Kitazaki</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>J</given-names></name><name><surname>Ii</surname><given-names>M</given-names></name><name><surname>Iizawa</surname><given-names>Y</given-names></name></person-group><article-title>Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model</article-title><source>Eur J Pharmacol</source><year>2007</year><volume>571</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2007.06.027</pub-id><pub-id pub-id-type="pmid">17632100</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>T</given-names></name><name><surname>Iizawa</surname><given-names>Y</given-names></name><name><surname>Ii</surname><given-names>M</given-names></name></person-group><article-title>Combination of imipenem and TAK-242, a Toll-like receptor 4 signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis</article-title><source>Shock</source><year>2011</year><volume>35</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1097/SHK.0b013e3181f48942</pub-id><pub-id pub-id-type="pmid">20720515</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tidswell</surname><given-names>M</given-names></name><name><surname>Tillis</surname><given-names>W</given-names></name><name><surname>Larosa</surname><given-names>SP</given-names></name><name><surname>Lynn</surname><given-names>M</given-names></name><name><surname>Wittek</surname><given-names>AE</given-names></name><name><surname>Kao</surname><given-names>R</given-names></name><name><surname>Wheeler</surname><given-names>J</given-names></name><name><surname>Gogate</surname><given-names>J</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name></person-group><article-title>Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><fpage>72</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181b07b78</pub-id><pub-id pub-id-type="pmid">19661804</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opal</surname><given-names>SM</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Francois</surname><given-names>B</given-names></name><name><surname>LaRosa</surname><given-names>SP</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Mira</surname><given-names>JP</given-names></name><name><surname>Wittebole</surname><given-names>X</given-names></name><name><surname>Dugernier</surname><given-names>T</given-names></name><name><surname>Perrotin</surname><given-names>D</given-names></name><name><surname>Tidswell</surname><given-names>M</given-names></name><name><surname>Jauregui</surname><given-names>L</given-names></name><name><surname>Krell</surname><given-names>K</given-names></name><name><surname>Pachl</surname><given-names>J</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Peckelsen</surname><given-names>C</given-names></name><name><surname>Cordasco</surname><given-names>E</given-names></name><name><surname>Chang</surname><given-names>CS</given-names></name><name><surname>Oeyen</surname><given-names>S</given-names></name><name><surname>Aikawa</surname><given-names>N</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Schein</surname><given-names>R</given-names></name><name><surname>Kalil</surname><given-names>AC</given-names></name><name><surname>Van Nuffelen</surname><given-names>M</given-names></name><name><surname>Lynn</surname><given-names>M</given-names></name><name><surname>Rossignol</surname><given-names>DP</given-names></name><name><surname>Gogate</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>MB</given-names></name><name><surname>Wheeler</surname><given-names>JL</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><collab>ACCESS Study Group</collab></person-group><article-title>Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial</article-title><source>JAMA</source><year>2013</year><volume>309</volume><fpage>1154</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.2194</pub-id><pub-id pub-id-type="pmid">23512062</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>TW</given-names></name><name><surname>Wheeler</surname><given-names>AP</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Aikawa</surname><given-names>N</given-names></name><name><surname>Demeyer</surname><given-names>I</given-names></name><name><surname>Sainati</surname><given-names>S</given-names></name><name><surname>Amlot</surname><given-names>N</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Ii</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Mouri</surname><given-names>K</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><fpage>1685</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181e7c5c9</pub-id><pub-id pub-id-type="pmid">20562702</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Achkar</surname><given-names>TM</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Plotkin</surname><given-names>Z</given-names></name><name><surname>Sandoval</surname><given-names>RM</given-names></name><name><surname>Rhodes</surname><given-names>GJ</given-names></name><name><surname>Dagher</surname><given-names>PC</given-names></name></person-group><article-title>Sepsis induces changes in the expression and distribution of Toll-like receptor 4 in the rat kidney</article-title><source>Am J Physiol Renal Physiol</source><year>2006</year><volume>290</volume><fpage>F1034</fpage><lpage>F1043</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00414.2005</pub-id><pub-id pub-id-type="pmid">16332927</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>PN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Quigg</surname><given-names>RJ</given-names></name></person-group><article-title>Role of Toll-like receptor 4 in endotoxin-induced acute renal failure</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>2629</fpage><lpage>2635</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.4.2629</pub-id><pub-id pub-id-type="pmid">14764737</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Egi</surname><given-names>M</given-names></name><name><surname>May</surname><given-names>CN</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>Renal blood flow in experimental septic acute renal failure</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><fpage>1996</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000440</pub-id><pub-id pub-id-type="pmid">16641923</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>K</given-names></name><name><surname>Leelahavanichkul</surname><given-names>A</given-names></name><name><surname>Yuen</surname><given-names>PS</given-names></name><name><surname>Star</surname><given-names>RA</given-names></name></person-group><article-title>Animal models of sepsis and sepsis-induced kidney injury</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><fpage>2868</fpage><lpage>2878</lpage><pub-id pub-id-type="doi">10.1172/JCI39421</pub-id><pub-id pub-id-type="pmid">19805915</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaitre</surname><given-names>B</given-names></name><name><surname>Nicolas</surname><given-names>E</given-names></name><name><surname>Michaut</surname><given-names>L</given-names></name><name><surname>Reichhart</surname><given-names>JM</given-names></name><name><surname>Hoffmann</surname><given-names>JA</given-names></name></person-group><article-title>The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults</article-title><source>Cell</source><year>1996</year><volume>86</volume><fpage>973</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80172-5</pub-id><pub-id pub-id-type="pmid">8808632</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>G</given-names></name><name><surname>Errea</surname><given-names>A</given-names></name><name><surname>Van Maele</surname><given-names>L</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>L&#x000e9;ger</surname><given-names>H</given-names></name><name><surname>Sirard</surname><given-names>JC</given-names></name><name><surname>Benecke</surname><given-names>A</given-names></name><name><surname>Rumbo</surname><given-names>M</given-names></name><name><surname>Hozbor</surname><given-names>D</given-names></name></person-group><article-title>Toll-like receptor 4 orchestrates neutrophil recruitment into airways during the first hours of Bordetella pertussis infection</article-title><source>Microbes Infect</source><year>2013</year><volume>15</volume><fpage>708</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2013.06.010</pub-id><pub-id pub-id-type="pmid">23811096</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsunaga</surname><given-names>N</given-names></name><name><surname>Tsuchimori</surname><given-names>N</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Ii</surname><given-names>M</given-names></name></person-group><article-title>TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules</article-title><source>Mol Pharmacol</source><year>2011</year><volume>79</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1124/mol.110.068064</pub-id><pub-id pub-id-type="pmid">20881006</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharfuddin</surname><given-names>AA</given-names></name><name><surname>Molitoris</surname><given-names>BA</given-names></name></person-group><article-title>Pathophysiology of ischemic acute kidney injury</article-title><source>Nat Rev Nephrol</source><year>2011</year><volume>7</volume><fpage>189</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2011.16</pub-id><pub-id pub-id-type="pmid">21364518</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>A</given-names></name><name><surname>Chokkalingam</surname><given-names>MB</given-names></name><name><surname>Mather</surname><given-names>PJ</given-names></name></person-group><article-title>Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms</article-title><source>Heart Fail Rev</source><year>2010</year><volume>15</volume><fpage>605</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1007/s10741-010-9176-4</pub-id><pub-id pub-id-type="pmid">20571889</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>May</surname><given-names>CN</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>The histopathology of septic acute kidney injury: a systematic review</article-title><source>Crit Care</source><year>2008</year><volume>12</volume><fpage>R38</fpage><pub-id pub-id-type="doi">10.1186/cc6823</pub-id><pub-id pub-id-type="pmid">18325092</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chawla</surname><given-names>LS</given-names></name><name><surname>Seneff</surname><given-names>MG</given-names></name><name><surname>Nelson</surname><given-names>DR</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>H</given-names></name><name><surname>Kimmel</surname><given-names>PL</given-names></name><name><surname>Macias</surname><given-names>WL</given-names></name></person-group><article-title>Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis</article-title><source>Clin J Am Soc Nephrol</source><year>2007</year><volume>2</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.2215/CJN.02510706</pub-id><pub-id pub-id-type="pmid">17699383</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>CN</given-names></name><name><surname>Calzavacca</surname><given-names>P</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Ramchandra</surname><given-names>R</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>Novel targets for sepsis-induced kidney injury: the glomerular arterioles and the sympathetic nervous system</article-title><source>Exp Physiol</source><year>2012</year><volume>97</volume><fpage>1168</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1113/expphysiol.2011.061804</pub-id><pub-id pub-id-type="pmid">22689445</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Calzavacca</surname><given-names>P</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>May</surname><given-names>CN</given-names></name></person-group><article-title>Effect of selective inhibition of renal inducible nitric oxide synthase on renal blood flow and function in experimental hyperdynamic sepsis</article-title><source>Crit Care Med</source><year>2012</year><volume>40</volume><fpage>2368</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3182514be9</pub-id><pub-id pub-id-type="pmid">22622397</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>B</given-names></name><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>Franck</surname><given-names>P</given-names></name><name><surname>Cravoisy</surname><given-names>A</given-names></name><name><surname>Bollaert</surname><given-names>PE</given-names></name></person-group><article-title>Relation between muscle Na&#x02009;+&#x02009;K&#x02009;+&#x02009;ATPase activity and raised lactate concentrations in septic shock: a prospective study</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>871</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)71045-X</pub-id><pub-id pub-id-type="pmid">15752531</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredriksson</surname><given-names>K</given-names></name><name><surname>Hammarqvist</surname><given-names>F</given-names></name><name><surname>Strigard</surname><given-names>K</given-names></name><name><surname>Hultenby</surname><given-names>K</given-names></name><name><surname>Ljungqvist</surname><given-names>O</given-names></name><name><surname>Wernerman</surname><given-names>J</given-names></name><name><surname>Rooyackers</surname><given-names>O</given-names></name></person-group><article-title>Derangements in mitochondrial metabolism in intercostal and leg muscle of critically ill patients with sepsis-induced multiple organ failure</article-title><source>Am J Physiol Endocrinol Metab</source><year>2006</year><volume>291</volume><fpage>E1044</fpage><lpage>E1050</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00218.2006</pub-id><pub-id pub-id-type="pmid">16803854</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Gokden</surname><given-names>N</given-names></name><name><surname>Mayeux</surname><given-names>PR</given-names></name></person-group><article-title>Evidence for the role of reactive nitrogen species in polymicrobial sepsis-induced renal peritubular capillary dysfunction and tubular injury</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>1807</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006121402</pub-id><pub-id pub-id-type="pmid">17494883</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharfuddin</surname><given-names>AA</given-names></name><name><surname>Sandoval</surname><given-names>RM</given-names></name><name><surname>Berg</surname><given-names>DT</given-names></name><name><surname>McDougal</surname><given-names>GE</given-names></name><name><surname>Campos</surname><given-names>SB</given-names></name><name><surname>Phillips</surname><given-names>CL</given-names></name><name><surname>Jones</surname><given-names>BE</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Grinnell</surname><given-names>BW</given-names></name><name><surname>Molitoris</surname><given-names>BA</given-names></name></person-group><article-title>Soluble thrombomodulin protects ischemic kidneys</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><fpage>524</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008060593</pub-id><pub-id pub-id-type="pmid">19176699</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soehnlein</surname><given-names>O</given-names></name><name><surname>Oehmcke</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Rothfuchs</surname><given-names>AG</given-names></name><name><surname>Frithiof</surname><given-names>R</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>M&#x000f6;rgelin</surname><given-names>M</given-names></name><name><surname>Herwald</surname><given-names>H</given-names></name><name><surname>Lindbom</surname><given-names>L</given-names></name></person-group><article-title>Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein</article-title><source>Eur Respir J</source><year>2008</year><volume>32</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1183/09031936.00173207</pub-id><pub-id pub-id-type="pmid">18321926</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>AS</given-names></name><name><surname>Rouse</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Vergis</surname><given-names>AL</given-names></name><name><surname>Reutershan</surname><given-names>J</given-names></name><name><surname>Cathro</surname><given-names>HP</given-names></name><name><surname>Linden</surname><given-names>J</given-names></name><name><surname>Okusa</surname><given-names>MD</given-names></name></person-group><article-title>Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury</article-title><source>Kidney Int</source><year>2009</year><volume>75</volume><fpage>689</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1038/ki.2008.648</pub-id><pub-id pub-id-type="pmid">19129795</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castoldi</surname><given-names>A</given-names></name><name><surname>Braga</surname><given-names>TT</given-names></name><name><surname>Correa-Costa</surname><given-names>M</given-names></name><name><surname>Aguiar</surname><given-names>CF</given-names></name><name><surname>Bassi</surname><given-names>EJ</given-names></name><name><surname>Correa-Silva</surname><given-names>R</given-names></name><name><surname>Elias</surname><given-names>RM</given-names></name><name><surname>Salvador</surname><given-names>F</given-names></name><name><surname>Moraes-Vieira</surname><given-names>PM</given-names></name><name><surname>Cenedeze</surname><given-names>MA</given-names></name><name><surname>Reis</surname><given-names>MA</given-names></name><name><surname>Hiyane</surname><given-names>MI</given-names></name><name><surname>Pacheco-Silva</surname><given-names>A</given-names></name><name><surname>Goncalves</surname><given-names>GM</given-names></name><name><surname>Saraiva Camara</surname><given-names>NO</given-names></name></person-group><article-title>TLR2, TLR4 and the MYD88 signaling pathway are crucial for neutrophil migration in acute kidney injury induced by sepsis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e37584</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0037584</pub-id><pub-id pub-id-type="pmid">22655058</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andonegui</surname><given-names>G</given-names></name><name><surname>Bonder</surname><given-names>CS</given-names></name><name><surname>Green</surname><given-names>F</given-names></name><name><surname>Mullaly</surname><given-names>SC</given-names></name><name><surname>Zbytnuik</surname><given-names>L</given-names></name><name><surname>Raharjo</surname><given-names>E</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group><article-title>Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><fpage>1011</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1172/JCI16510</pub-id><pub-id pub-id-type="pmid">12671050</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>John</surname><given-names>R</given-names></name><name><surname>Richardson</surname><given-names>JA</given-names></name><name><surname>Shelton</surname><given-names>JM</given-names></name><name><surname>Zhou</surname><given-names>XJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>QQ</given-names></name><name><surname>Hartono</surname><given-names>JR</given-names></name><name><surname>Winterberg</surname><given-names>PD</given-names></name><name><surname>Lu</surname><given-names>CY</given-names></name></person-group><article-title>Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury</article-title><source>Kidney Int</source><year>2011</year><volume>79</volume><fpage>288</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1038/ki.2010.381</pub-id><pub-id pub-id-type="pmid">20927041</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>HJ</given-names></name><name><surname>Lock</surname><given-names>HR</given-names></name><name><surname>Wolfs</surname><given-names>TG</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name><name><surname>Sacks</surname><given-names>SH</given-names></name><name><surname>Robson</surname><given-names>MG</given-names></name></person-group><article-title>Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><fpage>1732</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006060634</pub-id><pub-id pub-id-type="pmid">17460147</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Ramesh</surname><given-names>G</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Reeves</surname><given-names>WB</given-names></name></person-group><article-title>TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity</article-title><source>J Am Soc Nephrol</source><year>2008</year><volume>19</volume><fpage>923</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1681/ASN.2007090982</pub-id><pub-id pub-id-type="pmid">18256356</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molitoris</surname><given-names>BA</given-names></name><name><surname>Sandoval</surname><given-names>RM</given-names></name></person-group><article-title>Intravital multiphoton microscopy of dynamic renal processes</article-title><source>Am J Physiol Renal Physiol</source><year>2005</year><volume>288</volume><fpage>F1084</fpage><lpage>F1089</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00473.2004</pub-id><pub-id pub-id-type="pmid">15883167</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klausner</surname><given-names>JM</given-names></name><name><surname>Paterson</surname><given-names>IS</given-names></name><name><surname>Goldman</surname><given-names>G</given-names></name><name><surname>Kobzik</surname><given-names>L</given-names></name><name><surname>Rodzen</surname><given-names>C</given-names></name><name><surname>Lawrence</surname><given-names>R</given-names></name><name><surname>Valeri</surname><given-names>CR</given-names></name><name><surname>Shepro</surname><given-names>D</given-names></name><name><surname>Hechtman</surname><given-names>HB</given-names></name></person-group><article-title>Postischemic renal injury is mediated by neutrophils and leukotrienes</article-title><source>Am J Physiol</source><year>1989</year><volume>256</volume><fpage>F794</fpage><lpage>F802</lpage><pub-id pub-id-type="pmid">2541628</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>BA</given-names><suffix>III</suffix></name><name><surname>George</surname><given-names>T</given-names></name><name><surname>Sherwood</surname><given-names>ER</given-names></name><name><surname>Good</surname><given-names>DW</given-names></name></person-group><article-title>Basolateral LPS inhibits NHE3 and HCOFormula absorption through TLR4/MyD88-dependent ERK activation in medullary thick ascending limb</article-title><source>Am J Physiol Cell Physiol</source><year>2011</year><volume>301</volume><fpage>C1296</fpage><lpage>C1306</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00237.2011</pub-id><pub-id pub-id-type="pmid">21881005</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>BA</given-names><suffix>III</suffix></name><name><surname>George</surname><given-names>T</given-names></name><name><surname>Good</surname><given-names>DW</given-names></name></person-group><article-title>Lumen LPS inhibits HCO3(&#x02212;) absorption in the medullary thick ascending limb through TLR4-PI3K-Akt-mTOR-dependent inhibition of basolateral Na+/H&#x02009;+&#x02009;exchange</article-title><source>Am J Physiol Renal Physiol</source><year>2013</year><volume>305</volume><fpage>F451</fpage><lpage>F462</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00102.2013</pub-id><pub-id pub-id-type="pmid">23698118</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>BA</given-names><suffix>III</suffix></name><name><surname>George</surname><given-names>T</given-names></name><name><surname>Sherwood</surname><given-names>ER</given-names></name><name><surname>Good</surname><given-names>DW</given-names></name></person-group><article-title>A two-hit mechanism for sepsis-induced impairment of renal tubule function</article-title><source>Am J Physiol Renal Physiol</source><year>2013</year><volume>304</volume><fpage>F863</fpage><lpage>F874</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00608.2012</pub-id><pub-id pub-id-type="pmid">23324175</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Boesen</surname><given-names>EI</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>G</given-names></name><name><surname>Pollock</surname><given-names>JS</given-names></name><name><surname>Pollock</surname><given-names>DM</given-names></name></person-group><article-title>Novel use of ultrasound to examine regional blood flow in the mouse kidney</article-title><source>Am J Physiol Renal Physiol</source><year>2009</year><volume>297</volume><fpage>F228</fpage><lpage>F235</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00016.2009</pub-id><pub-id pub-id-type="pmid">19420115</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawaz</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>BH</given-names></name></person-group><article-title>Renal clearance of endogenous creatinine and urea in sheep during summer and winter</article-title><source>Res Vet Sci</source><year>1984</year><volume>36</volume><fpage>220</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">6718820</pub-id></element-citation></ref></ref-list></back></article>